Effect of growth hormone on human drug metabolism: time course and substrate specificity.
Replacement therapy for six weeks with human growth hormone (hGH) in deficient children has been shown to produce a significant lengthening of amobarbital t1/2. Studies to define the time course of this effect were carried out and indicate either no change or a minimal change after one to eight days of treatment. The increased t1/2 noted at six weeks persists for at least one year. In contrast to amobarbital, theophylline was found to exhibit a shortening of t1/2 from a mean of 7.52 +/- 4.44 (SD) to a mean of 3.38 +/- 1.23 hours in four subjects. Thus, replacement therapy with hGH results in quantitatively large but opposite changes in the elimination of these two drugs. For both substrates, however, t1/2 after hGH replacement more closely resembles values reported for normal subjects. This suggests that hGH may be a major determinant of in vivo drug elimination.
D000293:Adolescent; D000654:Amobarbital / Q000378:metabolism; D002648:Child; D004700:Endocrine System Diseases / Q000378:metabolism; D005260:Female; D013006:Growth Hormone / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans; D008297:Male; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011863:Radioimmunoassay; D013379:Substrate Specificity; D013806:Theophylline / Q000378:metabolism; D013997:Time Factors
D004364:Pharmaceutical Preparations; D013006:Growth Hormone; D013806:Theophylline; D000654:Amobarbital